Clinical Trial Update: Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, PK and effects on liver iron concentration of ICL670 relative to deferoxamine in sickle cell disease; results are…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Deferoxamine (deferoxamine)
• ICL670

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-01-20